We still don't know the true effectiveness of remdesivir. Photo: Ulrich Perrey/AFP via Getty Images

Depending on the study, remdesivir is either a clinical failure or a godsend for treating the novel coronavirus.

The big picture: The grim reality of the coronavirus pandemic has the world itching to know which experimental treatments actually work, but we're not necessarily getting any smarter from these incremental drips of incomplete information.

Driving the news: Remdesivir — an antiviral drug that some experts have seen as a promising coronavirus treatment — "was not associated with clinical or virological benefits" for coronavirus patients, according to a summary of a clinical trial in China, viewed by STAT and the Financial Times.

Between the lines: The truth is, we still don't really know how effective the drug is in fighting this virus.

  • The Chinese trial has a randomized control group, so it is by far the most reliable study. However, the trial has not gone through peer review, and Gilead said the results were "inconclusive" because the trial had to be terminated early.
  • The University of Chicago study and a Gilead-sponsored compassionate use study, which prompted rosier views of the drug, are riddled with flaws that make them hard to rely on. The most obvious drawback in both is the lack of a control group.

The bottom line: Science is slow for a reason, and the deluge of poorly designed trials and early drafts of studies is sowing confusion instead of creating clarity.

  • "The world is, unfortunately, getting a crash course in the value of evidence-based medicine vs. anecdote," veteran pharmaceutical analyst Brian Skorney tweeted.

What's next: A more rigorous report from Gilead's Chinese trial is expected at the end of this month, and data from other trials is expected in late May. Don't jump to any firm conclusions before that happens.

Go deeper: The high stakes of low scientific standards

Go deeper

Updated 5 hours ago - Health

World coronavirus updates

Data: The Center for Systems Science and Engineering at Johns Hopkins; Map: Axios Visuals

Australian officials in Victoria announced Sunday 17 more deaths from COVID-19 — a new state and national record.

The big picture: Australia was on track to suppress the novel coronavirus in May, but cases have been spiking in Victoria in recent weeks, where a state of disaster was declared last week, enabling officials to introduce restrictions including a night-time curfew in state capital Melbourne.

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 3 a.m. ET: 19,648,084 — Total deaths: 727,024 — Total recoveries — 11,941,723Map.
  2. U.S.: Total confirmed cases as of 3 a.m. ET: 4,998,105 — Total deaths: 162,425 — Total recoveries: 1,643,118 — Total tests: 61,080,587Map.
  3. Politics: Trump signs 4 executive actions on coronavirus aid — Democrats, and some Republicans, criticize the move
  4. Public health: Fauci says chances are "not great" that COVID-19 vaccine will be 98% effective — 1 in 3 Americans would decline COVID-19 vaccine.
  5. Science: Indoor air is the next coronavirus frontline.
  6. Schools: How back-to-school is playing out in the South as coronavirus rages on — Princeton, Johns Hopkins, Howard to hold fall classes online.

Trump says Fauci is "wrong" about coronavirus cases surge

President Trump and National Institute of Allergy and Infectious Diseases director Anthony Fauci during an April daily coronavirus task force briefing at the White House. Photo: Drew Angerer/Getty Images

President Trump called out Anthony Fauci Saturday in a comment retweeting a video of the NIAID director explaining why coronavirus cases have been surging in the U.S.

Driving the news: In the video of Friday's testimony, Fauci explained that while European countries shut 95% of their economies, the U.S. "functionally shut down only about 50%." Trump responded, "Wrong! We have more cases because we have tested far more than any other country, 60,000,000.